Anti-FLT3 antibodies
US8071099B2 · kind B2 · utility
10Cited by
6References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 27, 2010 |
| Grant date | Dec 6, 2011 |
| Priority date | — |
| Expiry date | Sep 27, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides fully human antibodies that specifically bind to human FLT3 within extracellular domains 4 or 5 with high affinity. The invention further provides methods of treating leukemia by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment including methotrexate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.